

Rutgers Cancer Institute Bone Marrow Transplant Tumor Board

Provided by Rutgers Cancer Institute, Department of Hematology

Interesting Cases of the Week
December 31, 2025 1:00-2:00 PM

Virtual: <https://rutgers.zoom.us/j/99371545348?pwd=5jRyJF1rnAlGR0P5nbqmgI43O4OyHW.1>

In-Person Location: Morris Cancer Center 4th Floor Conference Room 04-135

Matthew Matasar, MD & Jaqueline Manago, RN, BSN, BMTCN

Objectives

At the conclusion of this activity, participants should be better able to:

- Identify courses of treatment with presenting options from newly assigned guidelines by NCCN.
- Analyze oncological provider's opinions to identify approaches to patient management and care.
- Discuss clinical trials' specific eligibility criteria and treatment protocols.

Target Audience

This activity is designed for medical oncologists, pharmacists, surgical oncologists, general surgeons, radiation oncologists, radiologists, hematologists, pathologists, physician assistants, nurses, and nurse practitioners involved in Bone Marrow and Stem cell transplant.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 ANCC contact hour.

Pharmacists: This knowledge-based activity qualifies for 1 contact hour of continuing pharmacy education credit.

Disclosure Declarations

Presenters and Planning Committee: Matthew Matasar, MD has the following relevant financial relationships with ineligible companies: ADC Therapeutics, Allogene, Arvinas, AstraZeneca, Bristol Myers Squibb, Genentech, Genmab, Johnson & Johnson, Regeneron, Roche; Expert Witness: Bayer.

All of the relevant financial relationships listed have been mitigated.

Jacqueline Manago, RN, BSN, BMTCN (Content Reviewer) and Michael P. Kane, RPh, BCOP (Planner) have no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.